Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
| Autor: | M D, Tabone, J, Landman-Parker, B, Arcil, M C, Coudert, I, Gerota, M, Benbunan, G, Leverger, C, Dosquet |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Time Factors Adolescent Bone Neoplasms Enzyme-Linked Immunosorbent Assay Pilot Projects Endothelial Growth Factors Disease-Free Survival Neoplasms Humans Prospective Studies Neoplasm Metastasis Child Lymphokines Neovascularization Pathologic Vascular Endothelial Growth Factors Age Factors Infant Newborn Infant Prognosis Case-Control Studies Child Preschool Creatinine Female Fibroblast Growth Factor 2 |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research. 7(3) |
| ISSN: | 1078-0432 |
| Popis: | Angiogenesis plays an important role in the growth, progression, and metastasis of solid tumors. Among angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) appear to be useful markers in adults with cancer. The aim of this pilot study was to determine the levels of VEGF in serum and bFGF in serum and urine of children with solid tumor at diagnosis (as measured by ELISA), and to investigate whether these parameters provide prognostic information. Forty consecutive patients with different types of cancer were prospectively included in this study. Median values of all studied angiogenic factors were higher in patients than in controls (n = 40), and the differences were statistically significant for bFGF in serum and urine: 10 versus 3 pg/ml (P = 0.0004) and 6406 versus 0 pg/g of creatinine (P0.0001), respectively. Among patients, median serum values of bFGF and VEGF were higher in children with metastatic disease (n = 14) than in those with localized disease (n = 26). The difference was statistically significant for serum bFGF: 17.5 versus 6 pg/ml (P = 0.02). Serum angiogenic factor levels correlated with outcome. The estimated event-free survival at 3 years was 79% for patients with normal bFGF values (n = 13) versus 42% (n = 26; P = 0.02) for those with high levels, and 71% in case of normal VEGF values (n = 20) versus 38% (n = 19; P = 0.04) for those with high levels. No benefit of normal urinary bFGF values was observed. Our results provide a rationale for exploring the clinical interest of bFGF and VEGF measurements in body fluids of a larger group of children with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|